Work

Steroid Sidestep: Evading Androgen Ablation by Abiraterone

Year: 2014

Type: article

Abstract: Tumor mechanisms of abiraterone resistance in clinical prostate cancer are not well defined. Chen and colleagues report that a T878A androgen receptor mutation occurs in a subset of patients progressing while receiving abiraterone, suggesting that this may be a therapeutically exploitable mechanism of abiraterone resistance in castration-resistant prostate cancer. Clin Cancer Res; 21(6); 1240–2. ©2014 AACR. See related article by Chen et al., p. 1273

Source: Clinical Cancer Research

DOI: 10.1158/1078-0432.ccr-14-2899

Author: Nima Sharifi

Institution: Cleveland Clinic

Language: English

Topic: Prostate Cancer Treatment and Research

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: green

Funders: Howard Hughes Medical Institute, National Cancer Institute